Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
Pathogenic Consequences And Mechanistic Insights Of Daptomycin Resistance In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$540,633.00
Summary
Staphylococcus aureus is one of the most common human bacterial pathogens. This project aims to characterise the mechanisms that Staph uses to develop resistance to one of our last-line antibiotics, and will determine the effects of this resistance on the ability of the bacteria to cause human disease.
Combating The Reemergence Of Tuberculosis With New Vaccine Strategies
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Tuberculosis is a major global public health problem with significant morbidity and mortality. This project aims to generate new, highly efficacious vaccination regimens against tuberculosis, especially pulmonary tuberculosis, which is the most difficult manifestation of the disease to control. The outcomes of this project have the potential to save millions of lives worldwide and to decrease socioeconomic burden of tuberculosis, particularly in the context of HIV co-infection.
Mycobacterial Control Of The Establishment And Outcome Of Infection
Funder
National Health and Medical Research Council
Funding Amount
$311,956.00
Summary
Tuberculosis (TB) claims almost two million lives every year. TB subverts host immunity by directing the immune cells to launch an ineffective response to infection. One such trick is to hijack control of a class of molecules called eicosanoids from the host. This project will use a validated zebrafish model of TB infection to pinpoint the mechanisms used by mycobacteria to subvert normal eicosanoid production. Findings from this work may to aid the creation of novel anti-TB therapies.
New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.
Antibiotic Resistance And Host Immune Evasion In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$644,428.00
Summary
Staphylococcus aureus is one of the most common bacteria that infects humans. This project aims to characterise the mechanisms that Staph uses to develop resistance to one of our last-line antibiotics, and will determine the effects of this resistance on the ability of the bacteria to cause human disease. The work will also investigate new treatment strategies to tackle this challenging bacteria.
Infectious diseases plague mankind; with infections responsible for approximately 20% of all deaths worldwide. New strategies are urgently needed and we have positioned our research to address questions around how to forestall bacterial pathogens in the initial phases of invasion of human tissues and provide full understanding of the key molecules on the surfaces of bacterial cells. This fundamental knowledge is crucial to new drugs, vaccines and infection-resistant medical devices.
Role Of Hypoxia Inducible Factor In Innate Immune Function Against Gram-positive Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$241,352.00
Summary
Our society is currently facing the rise of drug-resistant pathogens ("superbugs") such as the potentially devastating methicillin-resistant Staphylococcus aureus, or _MRSA�. Recently, a molecule known as HIF has been shown to control the ability of our white blood cells to kill bacteria. This proposal aims to investigate the use of HIF boosting drugs to treat infections. These novel HIF agonists could be used alongside conventional antibiotics to improve infectious disease.
Clinical And Genomic Aspects Of Staphylococcus Aureus And Other Infectious Diseases In Northern Australia.
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The burden of infectious disease is high in Indigenous populations in northern Australia and patterns of disease differ. My research proposes to deepen our understanding of infectious diseases such as that due to Staphylococcus aureus (golden staph), hepatitis B and influenza by applying cutting-edge technologies (e.g., bacterial genomics) to answer clinically relevant questions. Ultimately I hope to prevent transmission of infections, improve vaccine strategies and find better targets for treat ....The burden of infectious disease is high in Indigenous populations in northern Australia and patterns of disease differ. My research proposes to deepen our understanding of infectious diseases such as that due to Staphylococcus aureus (golden staph), hepatitis B and influenza by applying cutting-edge technologies (e.g., bacterial genomics) to answer clinically relevant questions. Ultimately I hope to prevent transmission of infections, improve vaccine strategies and find better targets for treatment.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120101340
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Subversion of innate immune responses by pathogenic Escherichia coli. This project will determine how bacteria that cause diarrhoeal diseases prevent the immune system from signalling efficiently. It will provide important information not only about how the bacteria establish disease, but also provide insight into the host response in the early stages of infection.